Randomised, double‐blind, placebo‐controlled trial to assess the potential of cannabinoid receptor stimulation in the treatment of dystonia
Identifieur interne : 003166 ( Istex/Corpus ); précédent : 003165; suivant : 003167Randomised, double‐blind, placebo‐controlled trial to assess the potential of cannabinoid receptor stimulation in the treatment of dystonia
Auteurs : Susan H. Fox ; Mark Kellett ; A. Peter Moore ; Alan R. Crossman ; Jonathan M. BrotchieSource :
- Movement Disorders [ 0885-3185 ] ; 2002-01.
English descriptors
- KwdEn :
Abstract
Cannabis may have medicinal uses in a variety of diseases. The neural mechanisms underlying dystonia involve abnormalities within the basal ganglia—in particular, overactivity of the lateral globus pallidus (GPl). Cannabinoid receptors are located presynaptically on GABA terminals within the GPi, where their activation reduces GABA reuptake. Cannabinoid receptor stimulation may thus reduce overactivity of the GPl and thereby reduce dystonia. A double‐blind, randomised, placebo‐controlled, crossover study using the synthetic cannabinoid receptor agonist nabilone in patients with generalised and segmental primary dystonia showed no significant reduction in dystonia following treatment with nabilone. © 2001 Movement Disorder Society.
Url:
DOI: 10.1002/mds.1280
Links to Exploration step
ISTEX:820A66911789DED586603BDE2C38BCABB5D36D7CLe document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Randomised, double‐blind, placebo‐controlled trial to assess the potential of cannabinoid receptor stimulation in the treatment of dystonia</title><author><name sortKey="Fox, Susan H" sort="Fox, Susan H" uniqKey="Fox S" first="Susan H." last="Fox">Susan H. Fox</name><affiliation><mods:affiliation>Walton Centre for Neurology and Neurosurgery, Liverpool, United Kingdom</mods:affiliation></affiliation></author><author><name sortKey="Kellett, Mark" sort="Kellett, Mark" uniqKey="Kellett M" first="Mark" last="Kellett">Mark Kellett</name><affiliation><mods:affiliation>Walton Centre for Neurology and Neurosurgery, Liverpool, United Kingdom</mods:affiliation></affiliation><affiliation><mods:affiliation>Current Address: Department of Neurology, Hope Hospital, Stott Lane, Salford, Manchester M6 7HD, UK</mods:affiliation></affiliation></author><author><name sortKey="Moore, A Peter" sort="Moore, A Peter" uniqKey="Moore A" first="A. Peter" last="Moore">A. Peter Moore</name><affiliation><mods:affiliation>Walton Centre for Neurology and Neurosurgery, Liverpool, United Kingdom</mods:affiliation></affiliation></author><author><name sortKey="Crossman, Alan R" sort="Crossman, Alan R" uniqKey="Crossman A" first="Alan R." last="Crossman">Alan R. Crossman</name><affiliation><mods:affiliation>Manchester Movement Disorders Laboratory, Division of Neuroscience, School of Biological Sciences, University of Manchester, and Motac Neuroscience Ltd., Manchester Incubator Building, Manchester, United Kingdom</mods:affiliation></affiliation></author><author><name sortKey="Brotchie, Jonathan M" sort="Brotchie, Jonathan M" uniqKey="Brotchie J" first="Jonathan M." last="Brotchie">Jonathan M. Brotchie</name><affiliation><mods:affiliation>Manchester Movement Disorders Laboratory, Division of Neuroscience, School of Biological Sciences, University of Manchester, and Motac Neuroscience Ltd., Manchester Incubator Building, Manchester, United Kingdom</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:820A66911789DED586603BDE2C38BCABB5D36D7C</idno><date when="2002" year="2002">2002</date><idno type="doi">10.1002/mds.1280</idno><idno type="url">https://api.istex.fr/document/820A66911789DED586603BDE2C38BCABB5D36D7C/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">003166</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Randomised, double‐blind, placebo‐controlled trial to assess the potential of cannabinoid receptor stimulation in the treatment of dystonia</title><author><name sortKey="Fox, Susan H" sort="Fox, Susan H" uniqKey="Fox S" first="Susan H." last="Fox">Susan H. Fox</name><affiliation><mods:affiliation>Walton Centre for Neurology and Neurosurgery, Liverpool, United Kingdom</mods:affiliation></affiliation></author><author><name sortKey="Kellett, Mark" sort="Kellett, Mark" uniqKey="Kellett M" first="Mark" last="Kellett">Mark Kellett</name><affiliation><mods:affiliation>Walton Centre for Neurology and Neurosurgery, Liverpool, United Kingdom</mods:affiliation></affiliation><affiliation><mods:affiliation>Current Address: Department of Neurology, Hope Hospital, Stott Lane, Salford, Manchester M6 7HD, UK</mods:affiliation></affiliation></author><author><name sortKey="Moore, A Peter" sort="Moore, A Peter" uniqKey="Moore A" first="A. Peter" last="Moore">A. Peter Moore</name><affiliation><mods:affiliation>Walton Centre for Neurology and Neurosurgery, Liverpool, United Kingdom</mods:affiliation></affiliation></author><author><name sortKey="Crossman, Alan R" sort="Crossman, Alan R" uniqKey="Crossman A" first="Alan R." last="Crossman">Alan R. Crossman</name><affiliation><mods:affiliation>Manchester Movement Disorders Laboratory, Division of Neuroscience, School of Biological Sciences, University of Manchester, and Motac Neuroscience Ltd., Manchester Incubator Building, Manchester, United Kingdom</mods:affiliation></affiliation></author><author><name sortKey="Brotchie, Jonathan M" sort="Brotchie, Jonathan M" uniqKey="Brotchie J" first="Jonathan M." last="Brotchie">Jonathan M. Brotchie</name><affiliation><mods:affiliation>Manchester Movement Disorders Laboratory, Division of Neuroscience, School of Biological Sciences, University of Manchester, and Motac Neuroscience Ltd., Manchester Incubator Building, Manchester, United Kingdom</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>John Wiley & Sons, Inc.</publisher><pubPlace>New York</pubPlace><date type="published" when="2002-01">2002-01</date><biblScope unit="vol">17</biblScope><biblScope unit="issue">1</biblScope><biblScope unit="page" from="145">145</biblScope><biblScope unit="page" to="149">149</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">820A66911789DED586603BDE2C38BCABB5D36D7C</idno><idno type="DOI">10.1002/mds.1280</idno><idno type="ArticleID">MDS1280</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>cannabis</term><term>dystonia</term><term>globus pallidus</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Cannabis may have medicinal uses in a variety of diseases. The neural mechanisms underlying dystonia involve abnormalities within the basal ganglia—in particular, overactivity of the lateral globus pallidus (GPl). Cannabinoid receptors are located presynaptically on GABA terminals within the GPi, where their activation reduces GABA reuptake. Cannabinoid receptor stimulation may thus reduce overactivity of the GPl and thereby reduce dystonia. A double‐blind, randomised, placebo‐controlled, crossover study using the synthetic cannabinoid receptor agonist nabilone in patients with generalised and segmental primary dystonia showed no significant reduction in dystonia following treatment with nabilone. © 2001 Movement Disorder Society.</div></front></TEI><istex><corpusName>wiley</corpusName><author><json:item><name>Susan H. Fox MRCP, PhD</name><affiliations><json:string>Walton Centre for Neurology and Neurosurgery, Liverpool, United Kingdom</json:string></affiliations></json:item><json:item><name>Mark Kellett MRCP</name><affiliations><json:string>Walton Centre for Neurology and Neurosurgery, Liverpool, United Kingdom</json:string><json:string>Current Address: Department of Neurology, Hope Hospital, Stott Lane, Salford, Manchester M6 7HD, UK</json:string></affiliations></json:item><json:item><name>A. Peter Moore MRCP, MD</name><affiliations><json:string>Walton Centre for Neurology and Neurosurgery, Liverpool, United Kingdom</json:string></affiliations></json:item><json:item><name>Alan R. Crossman DSc</name><affiliations><json:string>Manchester Movement Disorders Laboratory, Division of Neuroscience, School of Biological Sciences, University of Manchester, and Motac Neuroscience Ltd., Manchester Incubator Building, Manchester, United Kingdom</json:string></affiliations></json:item><json:item><name>Jonathan M. Brotchie PhD</name><affiliations><json:string>Manchester Movement Disorders Laboratory, Division of Neuroscience, School of Biological Sciences, University of Manchester, and Motac Neuroscience Ltd., Manchester Incubator Building, Manchester, United Kingdom</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>dystonia</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>cannabis</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>globus pallidus</value></json:item></subject><language><json:string>eng</json:string></language><abstract>Cannabis may have medicinal uses in a variety of diseases. The neural mechanisms underlying dystonia involve abnormalities within the basal ganglia—in particular, overactivity of the lateral globus pallidus (GPl). Cannabinoid receptors are located presynaptically on GABA terminals within the GPi, where their activation reduces GABA reuptake. Cannabinoid receptor stimulation may thus reduce overactivity of the GPl and thereby reduce dystonia. A double‐blind, randomised, placebo‐controlled, crossover study using the synthetic cannabinoid receptor agonist nabilone in patients with generalised and segmental primary dystonia showed no significant reduction in dystonia following treatment with nabilone. © 2001 Movement Disorder Society.</abstract><qualityIndicators><score>3.715</score><pdfVersion>1.3</pdfVersion><pdfPageSize>612 x 792 pts (letter)</pdfPageSize><refBibsNative>true</refBibsNative><abstractCharCount>740</abstractCharCount><pdfWordCount>2563</pdfWordCount><pdfCharCount>17406</pdfCharCount><pdfPageCount>5</pdfPageCount><abstractWordCount>96</abstractWordCount></qualityIndicators><title>Randomised, double‐blind, placebo‐controlled trial to assess the potential of cannabinoid receptor stimulation in the treatment of dystonia</title><genre><json:string>Serial article</json:string></genre><host><volume>17</volume><pages><total>5</total><last>149</last><first>145</first></pages><issn><json:string>0885-3185</json:string></issn><issue>1</issue><subject><json:item><value>Brief Report</value></json:item></subject><genre></genre><language><json:string>unknown</json:string></language><title>Movement Disorders</title><doi><json:string>10.1002/(ISSN)1531-8257</json:string></doi></host><publicationDate>2002</publicationDate><copyrightDate>2002</copyrightDate><doi><json:string>10.1002/mds.1280</json:string></doi><id>820A66911789DED586603BDE2C38BCABB5D36D7C</id><fulltext><json:item><original>true</original><mimetype>application/pdf</mimetype><extension>pdf</extension><uri>https://api.istex.fr/document/820A66911789DED586603BDE2C38BCABB5D36D7C/fulltext/pdf</uri></json:item><json:item><original>false</original><mimetype>application/zip</mimetype><extension>zip</extension><uri>https://api.istex.fr/document/820A66911789DED586603BDE2C38BCABB5D36D7C/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/820A66911789DED586603BDE2C38BCABB5D36D7C/fulltext/tei"><teiHeader type="text"><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Randomised, double‐blind, placebo‐controlled trial to assess the potential of cannabinoid receptor stimulation in the treatment of dystonia</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>John Wiley & Sons, Inc.</publisher><pubPlace>New York</pubPlace><availability><p>John Wiley & Sons, Inc.</p></availability><date>2002</date></publicationStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">Randomised, double‐blind, placebo‐controlled trial to assess the potential of cannabinoid receptor stimulation in the treatment of dystonia</title><author><persName><forename type="first">Susan H.</forename><surname>Fox</surname><roleName type="degree">MRCP, PhD</roleName></persName><note type="correspondence"><p>Correspondence: Walton Centre for Neurology and Neurosurgery, Lower Lane, Fazakerley, Liverpool L9 7LJ, UK</p></note><affiliation>Walton Centre for Neurology and Neurosurgery, Liverpool, United Kingdom</affiliation></author><author><persName><forename type="first">Mark</forename><surname>Kellett</surname><roleName type="degree">MRCP</roleName></persName><affiliation>Walton Centre for Neurology and Neurosurgery, Liverpool, United Kingdom</affiliation><affiliation>Current Address: Department of Neurology, Hope Hospital, Stott Lane, Salford, Manchester M6 7HD, UK</affiliation></author><author><persName><forename type="first">A. Peter</forename><surname>Moore</surname><roleName type="degree">MRCP, MD</roleName></persName><affiliation>Walton Centre for Neurology and Neurosurgery, Liverpool, United Kingdom</affiliation></author><author><persName><forename type="first">Alan R.</forename><surname>Crossman</surname><roleName type="degree">DSc</roleName></persName><affiliation>Manchester Movement Disorders Laboratory, Division of Neuroscience, School of Biological Sciences, University of Manchester, and Motac Neuroscience Ltd., Manchester Incubator Building, Manchester, United Kingdom</affiliation></author><author><persName><forename type="first">Jonathan M.</forename><surname>Brotchie</surname><roleName type="degree">PhD</roleName></persName><affiliation>Manchester Movement Disorders Laboratory, Division of Neuroscience, School of Biological Sciences, University of Manchester, and Motac Neuroscience Ltd., Manchester Incubator Building, Manchester, United Kingdom</affiliation></author></analytic><monogr><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="pISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><idno type="DOI">10.1002/(ISSN)1531-8257</idno><imprint><publisher>John Wiley & Sons, Inc.</publisher><pubPlace>New York</pubPlace><date type="published" when="2002-01"></date><biblScope unit="vol">17</biblScope><biblScope unit="issue">1</biblScope><biblScope unit="page" from="145">145</biblScope><biblScope unit="page" to="149">149</biblScope></imprint></monogr><idno type="istex">820A66911789DED586603BDE2C38BCABB5D36D7C</idno><idno type="DOI">10.1002/mds.1280</idno><idno type="ArticleID">MDS1280</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>2002</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>Cannabis may have medicinal uses in a variety of diseases. The neural mechanisms underlying dystonia involve abnormalities within the basal ganglia—in particular, overactivity of the lateral globus pallidus (GPl). Cannabinoid receptors are located presynaptically on GABA terminals within the GPi, where their activation reduces GABA reuptake. Cannabinoid receptor stimulation may thus reduce overactivity of the GPl and thereby reduce dystonia. A double‐blind, randomised, placebo‐controlled, crossover study using the synthetic cannabinoid receptor agonist nabilone in patients with generalised and segmental primary dystonia showed no significant reduction in dystonia following treatment with nabilone. © 2001 Movement Disorder Society.</p></abstract><textClass xml:lang="en"><keywords scheme="keyword"><list><head>Keywords</head><item><term>dystonia</term></item><item><term>cannabis</term></item><item><term>globus pallidus</term></item></list></keywords></textClass><textClass><keywords scheme="Journal Subject"><list><head>Article category</head><item><term>Brief Report</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="2001-03-10">Received</change><change when="2001-07-12">Registration</change><change when="2002-01">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><original>false</original><mimetype>text/plain</mimetype><extension>txt</extension><uri>https://api.istex.fr/document/820A66911789DED586603BDE2C38BCABB5D36D7C/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>John Wiley & Sons, Inc.</publisherName><publisherLoc>New York</publisherLoc></publisherInfo><doi registered="yes">10.1002/(ISSN)1531-8257</doi><issn type="print">0885-3185</issn><issn type="electronic">1531-8257</issn><idGroup><id type="product" value="MDS"></id></idGroup><titleGroup><title type="main" xml:lang="en" sort="MOVEMENT DISORDERS">Movement Disorders</title><title type="short">Mov. Disord.</title></titleGroup></publicationMeta><publicationMeta level="part" position="10"><doi origin="wiley" registered="yes">10.1002/mds.v17:1</doi><numberingGroup><numbering type="journalVolume" number="17">17</numbering><numbering type="journalIssue">1</numbering></numberingGroup><coverDate startDate="2002-01">January/February 2002</coverDate></publicationMeta><publicationMeta level="unit" type="article" position="23" status="forIssue"><doi origin="wiley" registered="yes">10.1002/mds.1280</doi><idGroup><id type="unit" value="MDS1280"></id></idGroup><countGroup><count type="pageTotal" number="5"></count></countGroup><titleGroup><title type="articleCategory">Brief Report</title><title type="tocHeading1">Brief Report</title></titleGroup><copyright ownership="thirdParty">Copyright © 2002 Movement Disorder Society</copyright><eventGroup><event type="manuscriptReceived" date="2001-03-10"></event><event type="manuscriptRevised" date="2001-06-30"></event><event type="manuscriptAccepted" date="2001-07-12"></event><event type="firstOnline" date="2001-12-18"></event><event type="publishedOnlineFinalForm" date="2002-01-25"></event><event type="publishedOnlineAcceptedOrEarlyUnpaginated" date="2001-12-18"></event><event type="xmlConverted" agent="Converter:JWSART34_TO_WML3G version:2.4.7 mode:FullText source:FullText result:FullText" date="2011-02-24"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-02-02"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-11-01"></event></eventGroup><numberingGroup><numbering type="pageFirst">145</numbering><numbering type="pageLast">149</numbering></numberingGroup><correspondenceTo>Walton Centre for Neurology and Neurosurgery, Lower Lane, Fazakerley, Liverpool L9 7LJ, UK</correspondenceTo><linkGroup><link type="toTypesetVersion" href="file:MDS.MDS1280.pdf"></link></linkGroup></publicationMeta><contentMeta><countGroup><count type="figureTotal" number="1"></count><count type="tableTotal" number="2"></count><count type="referenceTotal" number="28"></count><count type="wordTotal" number="2488"></count></countGroup><titleGroup><title type="main" xml:lang="en">Randomised, double‐blind, placebo‐controlled trial to assess the potential of cannabinoid receptor stimulation in the treatment of dystonia</title><title type="short" xml:lang="en">Cannabinoids in Dystonia</title></titleGroup><creators><creator xml:id="au1" creatorRole="author" affiliationRef="#af1" corresponding="yes"><personName><givenNames>Susan H.</givenNames><familyName>Fox</familyName><degrees>MRCP, PhD</degrees></personName><contactDetails><email>shfox@hotmail.com</email></contactDetails></creator><creator xml:id="au2" creatorRole="author" affiliationRef="#af1" currentRef="#curr1"><personName><givenNames>Mark</givenNames><familyName>Kellett</familyName><degrees>MRCP</degrees></personName></creator><creator xml:id="au3" creatorRole="author" affiliationRef="#af1"><personName><givenNames>A. Peter</givenNames><familyName>Moore</familyName><degrees>MRCP, MD</degrees></personName></creator><creator xml:id="au4" creatorRole="author" affiliationRef="#af2"><personName><givenNames>Alan R.</givenNames><familyName>Crossman</familyName><degrees>DSc</degrees></personName></creator><creator xml:id="au5" creatorRole="author" affiliationRef="#af2"><personName><givenNames>Jonathan M.</givenNames><familyName>Brotchie</familyName><degrees>PhD</degrees></personName></creator></creators><affiliationGroup><affiliation xml:id="af1" countryCode="GB" type="organization"><unparsedAffiliation>Walton Centre for Neurology and Neurosurgery, Liverpool, United Kingdom</unparsedAffiliation></affiliation><affiliation xml:id="af2" countryCode="GB" type="organization"><unparsedAffiliation>Manchester Movement Disorders Laboratory, Division of Neuroscience, School of Biological Sciences, University of Manchester, and Motac Neuroscience Ltd., Manchester Incubator Building, Manchester, United Kingdom</unparsedAffiliation></affiliation><affiliation xml:id="curr1"><unparsedAffiliation>Department of Neurology, Hope Hospital, Stott Lane, Salford, Manchester M6 7HD, UK</unparsedAffiliation></affiliation></affiliationGroup><keywordGroup xml:lang="en" type="author"><keyword xml:id="kwd1">dystonia</keyword><keyword xml:id="kwd2">cannabis</keyword><keyword xml:id="kwd3">globus pallidus</keyword></keywordGroup><abstractGroup><abstract type="main" xml:lang="en"><title type="main">Abstract</title><p>Cannabis may have medicinal uses in a variety of diseases. The neural mechanisms underlying dystonia involve abnormalities within the basal ganglia—in particular, overactivity of the lateral globus pallidus (GPl). Cannabinoid receptors are located presynaptically on GABA terminals within the GPi, where their activation reduces GABA reuptake. Cannabinoid receptor stimulation may thus reduce overactivity of the GPl and thereby reduce dystonia. A double‐blind, randomised, placebo‐controlled, crossover study using the synthetic cannabinoid receptor agonist nabilone in patients with generalised and segmental primary dystonia showed no significant reduction in dystonia following treatment with nabilone. © 2001 Movement Disorder Society.</p></abstract></abstractGroup></contentMeta></header></component></istex:document></istex:metadataXml><!--Version 0.6 générée le 3-12-2015--><mods version="3.6"><titleInfo lang="en"><title>Randomised, double‐blind, placebo‐controlled trial to assess the potential of cannabinoid receptor stimulation in the treatment of dystonia</title></titleInfo><titleInfo type="abbreviated" lang="en"><title>Cannabinoids in Dystonia</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>Randomised, double‐blind, placebo‐controlled trial to assess the potential of cannabinoid receptor stimulation in the treatment of dystonia</title></titleInfo><name type="personal"><namePart type="given">Susan H.</namePart><namePart type="family">Fox</namePart><namePart type="termsOfAddress">MRCP, PhD</namePart><affiliation>Walton Centre for Neurology and Neurosurgery, Liverpool, United Kingdom</affiliation><description>Correspondence: Walton Centre for Neurology and Neurosurgery, Lower Lane, Fazakerley, Liverpool L9 7LJ, UK</description><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Mark</namePart><namePart type="family">Kellett</namePart><namePart type="termsOfAddress">MRCP</namePart><affiliation>Walton Centre for Neurology and Neurosurgery, Liverpool, United Kingdom</affiliation><affiliation>Current Address: Department of Neurology, Hope Hospital, Stott Lane, Salford, Manchester M6 7HD, UK</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">A. Peter</namePart><namePart type="family">Moore</namePart><namePart type="termsOfAddress">MRCP, MD</namePart><affiliation>Walton Centre for Neurology and Neurosurgery, Liverpool, United Kingdom</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Alan R.</namePart><namePart type="family">Crossman</namePart><namePart type="termsOfAddress">DSc</namePart><affiliation>Manchester Movement Disorders Laboratory, Division of Neuroscience, School of Biological Sciences, University of Manchester, and Motac Neuroscience Ltd., Manchester Incubator Building, Manchester, United Kingdom</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Jonathan M.</namePart><namePart type="family">Brotchie</namePart><namePart type="termsOfAddress">PhD</namePart><affiliation>Manchester Movement Disorders Laboratory, Division of Neuroscience, School of Biological Sciences, University of Manchester, and Motac Neuroscience Ltd., Manchester Incubator Building, Manchester, United Kingdom</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre authority="originalCategForm">article</genre><originInfo><publisher>John Wiley & Sons, Inc.</publisher><place><placeTerm type="text">New York</placeTerm></place><dateIssued encoding="w3cdtf">2002-01</dateIssued><dateCaptured encoding="w3cdtf">2001-03-10</dateCaptured><dateValid encoding="w3cdtf">2001-07-12</dateValid><copyrightDate encoding="w3cdtf">2002</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType><extent unit="figures">1</extent><extent unit="tables">2</extent><extent unit="references">28</extent><extent unit="words">2488</extent></physicalDescription><abstract lang="en">Cannabis may have medicinal uses in a variety of diseases. The neural mechanisms underlying dystonia involve abnormalities within the basal ganglia—in particular, overactivity of the lateral globus pallidus (GPl). Cannabinoid receptors are located presynaptically on GABA terminals within the GPi, where their activation reduces GABA reuptake. Cannabinoid receptor stimulation may thus reduce overactivity of the GPl and thereby reduce dystonia. A double‐blind, randomised, placebo‐controlled, crossover study using the synthetic cannabinoid receptor agonist nabilone in patients with generalised and segmental primary dystonia showed no significant reduction in dystonia following treatment with nabilone. © 2001 Movement Disorder Society.</abstract><subject lang="en"><genre>Keywords</genre><topic>dystonia</topic><topic>cannabis</topic><topic>globus pallidus</topic></subject><relatedItem type="host"><titleInfo><title>Movement Disorders</title></titleInfo><titleInfo type="abbreviated"><title>Mov. Disord.</title></titleInfo><subject><genre>article category</genre><topic>Brief Report</topic></subject><identifier type="ISSN">0885-3185</identifier><identifier type="eISSN">1531-8257</identifier><identifier type="DOI">10.1002/(ISSN)1531-8257</identifier><identifier type="PublisherID">MDS</identifier><part><date>2002</date><detail type="volume"><caption>vol.</caption><number>17</number></detail><detail type="issue"><caption>no.</caption><number>1</number></detail><extent unit="pages"><start>145</start><end>149</end><total>5</total></extent></part></relatedItem><identifier type="istex">820A66911789DED586603BDE2C38BCABB5D36D7C</identifier><identifier type="DOI">10.1002/mds.1280</identifier><identifier type="ArticleID">MDS1280</identifier><accessCondition type="use and reproduction" contentType="copyright">Copyright © 2002 Movement Disorder Society</accessCondition><recordInfo><recordOrigin>John Wiley & Sons, Inc.</recordOrigin><recordContentSource>WILEY</recordContentSource></recordInfo></mods></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003166 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 003166 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:820A66911789DED586603BDE2C38BCABB5D36D7C
|texte= Randomised, double‐blind, placebo‐controlled trial to assess the potential of cannabinoid receptor stimulation in the treatment of dystonia
}}
| This area was generated with Dilib version V0.6.23. |  |